BIOATLA
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that develops novel monoclonal antibody and cell-based therapeutics using our proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow them to develo... p novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment, even when the target is also found in normal tissue, not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.
BIOATLA
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.bioatla.com
Total Employee:
51+
Status:
Active
Contact:
1(858) 558-0708
Total Funding:
261.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
BionPharma
BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.
Pathway Genomics
Pathway Genomics is a CAP accredited global clinical lab offering genetic tests for cancer risk, drug responses, and other conditions.
Vital Therapies
Vital Therapies is a biotech company focused on developing a cell-based therapy targeting the treatment of acute liver failure.
Current Advisors List
Advisor
2021-08-01
Current Employees Featured
Jay M. Short Chairman, CEO and Cofounder @ BioAtla
Chairman, CEO and Cofounder
2007-03-01
Scott A. Smith President & Board Member @ BioAtla
President & Board Member
2018-09-01
Richard A. Waldron Chief Financial Officer @ BioAtla
Chief Financial Officer
Eric Sievers Chief Medical Officer @ BioAtla
Chief Medical Officer
2019-06-01
Founder
Stock Details
Investors List
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Post-IPO Equity - BioAtla
Pappas Capital
Pappas Capital investment in Post-IPO Equity - BioAtla
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Post-IPO Equity - BioAtla
Deerfield
Deerfield investment in Post-IPO Equity - BioAtla
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - BioAtla
Great Point Partners
Great Point Partners investment in Post-IPO Equity - BioAtla
Ikarian Capital
Ikarian Capital investment in Post-IPO Equity - BioAtla
Hudson Bay Capital Management
Hudson Bay Capital Management investment in Post-IPO Equity - BioAtla
Soleus Capital
Soleus Capital investment in Post-IPO Equity - BioAtla
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - BioAtla
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2017-02-16 | Exuma Biotech | BioAtla investment in Series A - Exuma Biotech | 37 M USD |
Official Site Inspections
http://www.bioatla.com Semrush global rank: 4.17 M Semrush visits lastest month: 2.85 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "BioAtla"
About Us - BioAtla
About Us Profile BioAtla© develops novel therapies with improved therapeutic index that have the potential to revolutionize cancer treatment. BioAtla© is a San Diego biotech company that …See details»
BioAtla - Crunchbase Company Profile & Funding
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. BioAtla is a San Diego biotech company that …See details»
BioAtla, Inc. - LinkedIn
BioAtla, Inc. | 5,597 followers on LinkedIn. BioAtla is a protein therapeutic company that uses discovery and evolution to develop safer and more potent drugs for the treatment of cancer. The ...See details»
BioAtla, Inc. Announces Registered Direct Offering to Advance …
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the …See details»
BioAtla Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 BioAtla is a biopharmaceutical company that develops drugs for cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate …See details»
202 Annual Report - BioAtla, Inc
BIOATLA, INC. (Exact name of registrant as specified in its charter) Delaware 85-1922320 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 11085 …See details»
BioAtla, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore BioAtla, Inc. with its drug pipeline, therapeutic area, technology platform, 7 clinical trials, 83 news, and 4 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, …See details»
Working At BioAtla: Company Overview and Culture - Zippia
BioAtla is a small education organization based in San Diego, CA with only 36 employees and an annual revenue of $250,000. BioAtla's Mission Statement BioAtla© develops novel therapies …See details»
BioAtla - Contacts, Employees, Board Members, Advisors & Alumni
BioAtla develops safer, more effective drugs for cancer using a proprietary next-generation antibody discovery and evolution platform. ... Experience the new Crunchbase, powered by AI …See details»
BioAtla - Funding, Financials, Valuation & Investors - Crunchbase
BioAtla is registered under the ticker NASDAQ:BCAB . Their stock opened with $18.00 in its Dec 15, 2020 IPO. BioAtla is funded by 20 investors. Vivo Capital and Acuta Capital Partners are …See details»
BioAtla - Leadership Team - The Org
The Leadership Team at BioAtla is responsible for setting the strategic direction and fostering a collaborative culture to drive the development of innovative cancer therapies. Comprising key …See details»
Bioatla, Inc | Reagan-Udall Foundation
• Any condition, in addition to those listed above, that in the opinion of BioAtla may preclude appropriate use of the investigational medicine, will be considered. Subscribe for updates from …See details»
BioAtla - Corporate Governance Guidelines
BIOATLA, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) has adopted these corporate governance guidelines to assist …See details»
BioAtla Announces Upcoming Poster Presentation at the IASLC …
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active …See details»
Breakthrough antibody technology to broaden therapeutic
BioAtla at a Glance Technology • Proprietary CAB technology creates antibodies that conditionally and reversibly bind to tumors, but not normal cells, enabling increased antibody potency and …See details»
BioAtla Reports Fourth Quarter and Full Year 2024 Financial
38 minutes ago BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on …See details»
BioAtla Inc - Company Profile - Market Research Reports
BioAtla Inc (BioAtla) is a clinical-stage biopharmaceutical company that develops novel therapies for the treatment of solid tumor cancer. The company product candidate includes BA3011, …See details»
BioAtla, Inc. (BioAtla, Inc.) - 药物管线_专利_临床试验_投融营收_最 …
了解BioAtla, Inc. (BioAtla, Inc.)公司的药物管线，治疗领域，技术平台，以及它的7项临床试验, 84篇新闻和4篇文献，疾病领域:肿瘤，内分泌与代谢疾病，神经系统疾病，技术平台:双特异 …See details»
BioAtla Reports Improved Survival Outcomes in NSCLC Patients …
Dec 16, 2024 BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro …See details»
Earnings Outlook For BioAtla - BioAtla (NASDAQ:BCAB)
1 day ago Analysts anticipate BioAtla to report an earnings per share (EPS) of $-0.38. Investors in BioAtla are eagerly awaiting the company's announcement, hoping for news of surpassing …See details»